Cargando…

Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis

The addition of platinum compounds to standard neoadjuvant chemotherapy (NACT) for triple-negative breast cancer (TNBC) is highly controversial. Platinum agents, such as cisplatin and carboplatin, are DNA-damaging agents which exhibit activity in breast cancer, particularly in the TNBC subgroup. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Vidra, Radu, Nemes, Adina, Vidrean, Andreea, Pintea, Sebastian, Tintari, Snejeana, Deac, Andrada, Ciuleanu, Tudor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652390/
https://www.ncbi.nlm.nih.gov/pubmed/34934456
http://dx.doi.org/10.3892/etm.2021.11014
_version_ 1784611585127350272
author Vidra, Radu
Nemes, Adina
Vidrean, Andreea
Pintea, Sebastian
Tintari, Snejeana
Deac, Andrada
Ciuleanu, Tudor
author_facet Vidra, Radu
Nemes, Adina
Vidrean, Andreea
Pintea, Sebastian
Tintari, Snejeana
Deac, Andrada
Ciuleanu, Tudor
author_sort Vidra, Radu
collection PubMed
description The addition of platinum compounds to standard neoadjuvant chemotherapy (NACT) for triple-negative breast cancer (TNBC) is highly controversial. Platinum agents, such as cisplatin and carboplatin, are DNA-damaging agents which exhibit activity in breast cancer, particularly in the TNBC subgroup. In order to assess the efficacy of each most representative platinum agent (cisplatin and carboplatin) in patients with TNBC treated with NACT, the present study performed a systematic review and meta-analysis of all available published studies on TNBC. A search of PubMed was performed to identify studies that investigated platinum-based NACT in patients with TNBC. The primary endpoints were the pooled rate of the pathological complete response (pCR) between cisplatin vs. carboplatin-based NACT. A total of 24 studies were selected (17 studies for carboplatin and 6 studies for cisplatin and 1 study with both carboplatin and cisplatin, with 20 prospective studies) for the analysis of 1,711 patients with TNBC. Overall, the pooled rate of pCR in patients treated with platinum-based NACT was 48%. No significant differences were observed between the rates of pCR obtained under carboplatin vs cisplatin treatment. The carboplatin pCR rate was 0.470 [95% confidence interval (CI), 0.401-0.539], while the cisplatin pCR rate was 0.473 (95% CI, 0.379-0.568). The comparison between these two categories revealed no significant differences (P=0.959). In the whole, the present study demonstrates that neoadjuvant platinum-based chemotherapy improves the pCR rate in patients with TNBC, regardless of the platinum agent used. Carboplatin may thus represent a viable option due to its more favorable toxicity profile.
format Online
Article
Text
id pubmed-8652390
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-86523902021-12-20 Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis Vidra, Radu Nemes, Adina Vidrean, Andreea Pintea, Sebastian Tintari, Snejeana Deac, Andrada Ciuleanu, Tudor Exp Ther Med Articles The addition of platinum compounds to standard neoadjuvant chemotherapy (NACT) for triple-negative breast cancer (TNBC) is highly controversial. Platinum agents, such as cisplatin and carboplatin, are DNA-damaging agents which exhibit activity in breast cancer, particularly in the TNBC subgroup. In order to assess the efficacy of each most representative platinum agent (cisplatin and carboplatin) in patients with TNBC treated with NACT, the present study performed a systematic review and meta-analysis of all available published studies on TNBC. A search of PubMed was performed to identify studies that investigated platinum-based NACT in patients with TNBC. The primary endpoints were the pooled rate of the pathological complete response (pCR) between cisplatin vs. carboplatin-based NACT. A total of 24 studies were selected (17 studies for carboplatin and 6 studies for cisplatin and 1 study with both carboplatin and cisplatin, with 20 prospective studies) for the analysis of 1,711 patients with TNBC. Overall, the pooled rate of pCR in patients treated with platinum-based NACT was 48%. No significant differences were observed between the rates of pCR obtained under carboplatin vs cisplatin treatment. The carboplatin pCR rate was 0.470 [95% confidence interval (CI), 0.401-0.539], while the cisplatin pCR rate was 0.473 (95% CI, 0.379-0.568). The comparison between these two categories revealed no significant differences (P=0.959). In the whole, the present study demonstrates that neoadjuvant platinum-based chemotherapy improves the pCR rate in patients with TNBC, regardless of the platinum agent used. Carboplatin may thus represent a viable option due to its more favorable toxicity profile. D.A. Spandidos 2022-01 2021-11-26 /pmc/articles/PMC8652390/ /pubmed/34934456 http://dx.doi.org/10.3892/etm.2021.11014 Text en Copyright: © Vidra et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Vidra, Radu
Nemes, Adina
Vidrean, Andreea
Pintea, Sebastian
Tintari, Snejeana
Deac, Andrada
Ciuleanu, Tudor
Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis
title Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis
title_full Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis
title_fullStr Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis
title_full_unstemmed Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis
title_short Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis
title_sort pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652390/
https://www.ncbi.nlm.nih.gov/pubmed/34934456
http://dx.doi.org/10.3892/etm.2021.11014
work_keys_str_mv AT vidraradu pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis
AT nemesadina pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis
AT vidreanandreea pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis
AT pinteasebastian pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis
AT tintarisnejeana pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis
AT deacandrada pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis
AT ciuleanutudor pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis